{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:45Z","timestamp":1786649925285,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) are highly effective therapies for chronic myeloid leukemia (CML). However, continuous administration of TKIs could lead to toxicity that could induce serious vascular disorders. Nilotinib, a second-generation TKI, has been approved for patients with CML in the chronic phase or accelerated phase, after resistance to imatinib has been identified, or as a first-line treatment. In comparison to other TKIs, nilotinib has been associated with a higher incidence of cardiovascular events, such as peripheral artery occlusive disease. We present a CML patient who developed acute ischemic bowel necrosis and perforation during nilotinib therapy.<\/jats:p>","DOI":"10.4103\/njcp.njcp_33_18","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T06:21:14Z","timestamp":1692598874000},"page":"131-133","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Acute Ischemic Intestinal Necrosis as a Rare Side Effect of Nilotinib"],"prefix":"10.4103","volume":"22","author":[{"given":"L","family":"Li","sequence":"first","affiliation":[{"name":"Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Zeng","sequence":"additional","affiliation":[{"name":"Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Chen","sequence":"additional","affiliation":[{"name":"Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251006","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"R3-20251006","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","article-title":"Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase","volume":"30","author":"Gu\u00e9rin","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"R5-20251006","first-page":"1395","article-title":"Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: Preferential occurrence in patients with comorbidities","volume":"96","author":"Valent","year":"2011","journal-title":"Haematologica"},{"key":"R6-20251006","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jacc.2005.10.009","article-title":"ACC\/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery\/Society for Vascular Surgery, Society for Cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC\/AHA task force on practice guidelines (Writing committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic inter-Society Consensus; and Vascular Disease Foundation","volume":"47","author":"Hirsch","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11523-016-0417-x","article-title":"Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy","volume":"11","author":"Bondon-Guitton","year":"2016","journal-title":"Target Oncol"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01253091-201922010-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:58Z","timestamp":1786647598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01253091-201922010-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_33_18","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2018-08-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}